CRMD: Diversified portfolio, robust cash, and new indications position the company for strong institutional growth
The company has transformed into a diversified specialty pharma with eight marketed products and a scalable institutional platform. DefenCath’s reimbursement transition and Medicare Advantage efforts are key near-term drivers, while REZZAYO’s prophylaxis indication could significantly expand its ma…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.